Hanna Cho
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Hanna Cho has a total of 372 co-authors. Here are the top co-authors by number of shared publications:
- Chul Hyoung Lyoo
Department of Neurology Gangnam Severance Hospital, Yonsei University College of Medicine Seoul South Korea
34 shared publications Hee Jin Kim
Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
28 shared publications- Young Hoon Ryu
Department of Nuclear Medicine, Gangnam Severance Hospital, Yonsei University, College of Medicine, Seoul, South Korea
27 shared publications Duk L. Na
Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
25 shared publications- Sang Won Seo
Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
23 shared publications Geon Ha Kim
Department of Neurology, Ewha Womans University Mokdong Hospital, Ewha Womans University School of Medicine, Seoul, Republic of Korea
20 shared publications
Latest Publications
- Open Access
- 17 February 2026
- Published by Wiley in Alzheimer's & Dementia
- Vol. 22 (2) , e71199
Plasma p‐tau217 predicts PET‐based pathological staging for precision Alzheimer disease assessment
INTRODUCTION: While positron emission tomography (PET) is the standard for pathological staging, its limited availability necessitates accessible alternatives. We evaluated plasma biomarkers for detecting PET‐based stages using single‐axis (Thal/Braak) and integrated A/T composite models. METHODS: We enrolled 237 AD spectrum participants undergoing multimodal assessments including amyloid/tau PET and plasma biomarker analysis (phosphorylated tau [p‐tau] 217, %p‐tau217, and amyloid beta [Aβ] 42/40 ratio). Detecting and discriminative performance was assessed using receiver operating characteristics (ROC) analysis and probability‐based stage prediction. RESULTS: Plasma p‐tau217‐based biomarkers showed excellent detecting performance for early amyloid (Thal I–II; area under the curve values > 0.96) and intermediate tau (Braak III–IV; area under the curve values > 0.92). Probability‐based prediction identified therapeutic window thresholds of 1.895–5.077 pg/mL. Notably, integrated A/T composite staging yielded highly consistent thresholds (< 3% variance). DISCUSSION: Plasma p‐tau217‐based biomarkers accurately reflect PET‐based staging across frameworks. The convergent therapeutic window thresholds demonstrate robust biological transitions, enabling accessible identification of optimal candidates for disease‐modifying therapies.
- 17 February 2026
- Published by Wiley in Alzheimer's & Dementia
- Vol. 22 (2) , e71199
Open AccessPlasma p‐tau217 predicts PET‐based pathological staging for precision Alzheimer disease assessment
INTRODUCTION: While positron emission tomography (PET) is the standard for pathological staging, its limited availability necessitates accessible alternatives. We evaluated plasma biomarkers for detecting PET‐based stages using single‐axis (Thal/Braak) and integrated A/T composite models. METHODS: We enrolled 237 AD spectrum participants undergoing multimodal assessments including amyloid/tau PET and plasma biomarker analysis (phosphorylated tau [p‐tau] 217, %p‐tau217, and amyloid beta [Aβ] 42/40 ratio). Detecting and discriminative performance was assessed using receiver operating characteristics (ROC) analysis and probability‐based stage prediction. RESULTS: Plasma p‐tau217‐based biomarkers showed excellent detecting performance for early amyloid (Thal I–II; area under the curve values > 0.96) and intermediate tau (Braak III–IV; area under the curve values > 0.92). Probability‐based prediction identified therapeutic window thresholds of 1.895–5.077 pg/mL. Notably, integrated A/T composite staging yielded highly consistent thresholds (< 3% variance). DISCUSSION: Plasma p‐tau217‐based biomarkers accurately reflect PET‐based staging across frameworks. The convergent therapeutic window thresholds demonstrate robust biological transitions, enabling accessible identification of optimal candidates for disease‐modifying therapies.
- Open Access
- 1 January 2026
- Published by XMLink in Dementia and Neurocognitive Disorders
- Vol. 25 (1) , 25-41
A Protocol of Korean JOint RegistrY for ALZheimer’s Treatment and Diagnostics (JOY-ALZ)
Background and Purpose: To assess the long-term effectiveness, safety, and economic viability of recently approved Alzheimer's disease (AD) therapies, as well as to evaluate the real-world application of novel diagnostics among AD patients with diverse comorbidities, comprehensive real-world data (RWD) analysis is essential. The Korean JOint RegistrY for ALZheimer's Treatment and Diagnostics (JOY-ALZ) endeavors to create a registry of RWD derived from clinical practice on new diagnostic methods and therapeutic agents for AD introduced in Korea since 2021. Methods: Participants must fulfill all the following: 1) be at least 19 years old; 2) be actively receiving, scheduled to initiate, or undergoing evaluation for any AD disease-modifying treatment; 3) have completed amyloid positron emission tomography or cerebrospinal fluid AD immunoassay (a positive result is not essential for participation); 4) have a
- 1 January 2026
- Published by XMLink in Dementia and Neurocognitive Disorders
- Vol. 25 (1) , 25-41
Open AccessA Protocol of Korean JOint RegistrY for ALZheimer’s Treatment and Diagnostics (JOY-ALZ)
Background and Purpose: To assess the long-term effectiveness, safety, and economic viability of recently approved Alzheimer's disease (AD) therapies, as well as to evaluate the real-world application of novel diagnostics among AD patients with diverse comorbidities, comprehensive real-world data (RWD) analysis is essential. The Korean JOint RegistrY for ALZheimer's Treatment and Diagnostics (JOY-ALZ) endeavors to create a registry of RWD derived from clinical practice on new diagnostic methods and therapeutic agents for AD introduced in Korea since 2021. Methods: Participants must fulfill all the following: 1) be at least 19 years old; 2) be actively receiving, scheduled to initiate, or undergoing evaluation for any AD disease-modifying treatment; 3) have completed amyloid positron emission tomography or cerebrospinal fluid AD immunoassay (a positive result is not essential for participation); 4) have a
- Open Access
- 23 December 2025
- Published by Wiley in Alzheimer's & Dementia
- Vol. 21 (S6) , e104782
Social Determinants of Health as Predictors of Accelerated Alzheimer's Disease Biomarker Accumulation and Cognitive Deterioration
Background: Social Determinants of Health (SDOH), including education and socioeconomic status, are known to influence cognitive health and dementia risk in older adults. However, the mechanisms by which SDOH affect brain health, particularly Alzheimer's disease (AD) biomarkers, are not well understood. This study aimed to explore the impact of socioeconomic disparities on the progression of AD biomarkers over time. Methods: This retrospective study examined participants undergoing longitudinal evaluation of AD biomarkers: amyloid, tau, and neurodegeneration (ATN), using dual positron emission tomography (PET) with 18 F‐Florbetaben and 18 F‐Flortaucipir, brain MRI, and neuropsychological assessments. Participants were classified into low, middle, and high SDOH groups based on a composite score reflecting education, income, residential area, and comorbid vascular risk factors. Linear mixed models were used to assess changes in amyloid and tau accumulation and cognitive performance across SDOH groups, adjusting for age, sex, education, APOE genotype, and cognitive status. Results: The study included 185 participants (healthy controls, n = 77; mild cognitive impairment, n = 75; dementia, n = 33), with 73 participants (39.5%) testing positive for amyloid on PET scans. Cross‐sectional analyses showed no significant differences in amyloid or tau burden across the SDOH groups. Among amyloid‐positive individuals, the low SDOH group had a significantly faster rate of tau accumulation compared to the middle ( p = 0.006) and high SDOH groups ( p = 0.002). Additionally, the low SDOH group exhibited a more rapid decline in cognitive performance, particularly in language and visuospatial domains. Among amyloid‐negative participants at baseline, the low SDOH group showed faster amyloid accumulation ( p = 0.0186) and greater decline in language function ( p = 0.009) compared to the high SDOH group. Conclusions: These findings suggest that disadvantaged SDOH are associated with accelerated AD progression, including faster tau accumulation in amyloid‐positive individuals and more rapid amyloid accumulation in amyloid‐negative individuals. The results highlight the importance of incorporating SDOH in clinical trials and the need for targeted interventions for those in the low SDOH group.
- 23 December 2025
- Published by Wiley in Alzheimer's & Dementia
- Vol. 21 (S6) , e104782
Open AccessSocial Determinants of Health as Predictors of Accelerated Alzheimer's Disease Biomarker Accumulation and Cognitive Deterioration
Background: Social Determinants of Health (SDOH), including education and socioeconomic status, are known to influence cognitive health and dementia risk in older adults. However, the mechanisms by which SDOH affect brain health, particularly Alzheimer's disease (AD) biomarkers, are not well understood. This study aimed to explore the impact of socioeconomic disparities on the progression of AD biomarkers over time. Methods: This retrospective study examined participants undergoing longitudinal evaluation of AD biomarkers: amyloid, tau, and neurodegeneration (ATN), using dual positron emission tomography (PET) with 18 F‐Florbetaben and 18 F‐Flortaucipir, brain MRI, and neuropsychological assessments. Participants were classified into low, middle, and high SDOH groups based on a composite score reflecting education, income, residential area, and comorbid vascular risk factors. Linear mixed models were used to assess changes in amyloid and tau accumulation and cognitive performance across SDOH groups, adjusting for age, sex, education, APOE genotype, and cognitive status. Results: The study included 185 participants (healthy controls, n = 77; mild cognitive impairment, n = 75; dementia, n = 33), with 73 participants (39.5%) testing positive for amyloid on PET scans. Cross‐sectional analyses showed no significant differences in amyloid or tau burden across the SDOH groups. Among amyloid‐positive individuals, the low SDOH group had a significantly faster rate of tau accumulation compared to the middle ( p = 0.006) and high SDOH groups ( p = 0.002). Additionally, the low SDOH group exhibited a more rapid decline in cognitive performance, particularly in language and visuospatial domains. Among amyloid‐negative participants at baseline, the low SDOH group showed faster amyloid accumulation ( p = 0.0186) and greater decline in language function ( p = 0.009) compared to the high SDOH group. Conclusions: These findings suggest that disadvantaged SDOH are associated with accelerated AD progression, including faster tau accumulation in amyloid‐positive individuals and more rapid amyloid accumulation in amyloid‐negative individuals. The results highlight the importance of incorporating SDOH in clinical trials and the need for targeted interventions for those in the low SDOH group.
- Open Access
- 22 June 2025
- Published by Wiley in Alzheimer's & Dementia
- Vol. 21 (6) , e70352
Integrating visual assessments and quantification methods for tau PET staging
INTRODUCTION: We compared visual assessments and quantification methods for tau positron emission tomography (PET) staging and evaluated plasma biomarkers and cognitive trajectories across amyloid and tau (AT) staging.METHODS: Tau PET scans from 289 Korea‐Registries to Overcome Dementia and Accelerate Dementia Research (K‐ROAD) participants were analyzed visually and quantitatively, with validation in the Alzheimer's Disease Neuroimaging Initiative (ADNI) cohort (n = 870). Plasma biomarkers and cognitive measures were evaluated across AT stages.RESULTS: FreeSurfer without partial volume correction (PVC) achieved the highest area under the curve (AUC) for tau positivity (0.918), based on visual interpretation. The temporal meta‐region excelled in moderate tau staging (AUC = 0.856), while the temporoparietal region performed best for advanced staging (AUC = 0.828). Quantification methods detected phosphorylated tau217 changes during intermediate transitions (e.g., A+/T− to A+/Tmod+) more effectively. Plasma biomarkers and cognitive measures progressively changed across AT stages, with consistent results in K‐ROAD and ADNI cohorts.DISCUSSION: The complementary strengths of visual and quantification methods enhance tau PET staging by effectively capturing biomarker changes and cognitive trajectories.Highlights: Quantification partially outperformed visual assessments in detecting early tau burdens. Meta‐temporal and temporoparietal regions of interest excelled in early and late tau staging. Quantification methods correlated with plasma phosphorylated tau217 and cognitive decline. Findings were validated across two independent cohorts (Korea‐Registries to Overcome Dementia and Accelerate Dementia Research and Alzheimer's Disease Neuroimaging Initiative). The study highlights the complementary roles of visual and quantification methods.
- 22 June 2025
- Published by Wiley in Alzheimer's & Dementia
- Vol. 21 (6) , e70352
Open AccessIntegrating visual assessments and quantification methods for tau PET staging
INTRODUCTION: We compared visual assessments and quantification methods for tau positron emission tomography (PET) staging and evaluated plasma biomarkers and cognitive trajectories across amyloid and tau (AT) staging.METHODS: Tau PET scans from 289 Korea‐Registries to Overcome Dementia and Accelerate Dementia Research (K‐ROAD) participants were analyzed visually and quantitatively, with validation in the Alzheimer's Disease Neuroimaging Initiative (ADNI) cohort (n = 870). Plasma biomarkers and cognitive measures were evaluated across AT stages.RESULTS: FreeSurfer without partial volume correction (PVC) achieved the highest area under the curve (AUC) for tau positivity (0.918), based on visual interpretation. The temporal meta‐region excelled in moderate tau staging (AUC = 0.856), while the temporoparietal region performed best for advanced staging (AUC = 0.828). Quantification methods detected phosphorylated tau217 changes during intermediate transitions (e.g., A+/T− to A+/Tmod+) more effectively. Plasma biomarkers and cognitive measures progressively changed across AT stages, with consistent results in K‐ROAD and ADNI cohorts.DISCUSSION: The complementary strengths of visual and quantification methods enhance tau PET staging by effectively capturing biomarker changes and cognitive trajectories.Highlights: Quantification partially outperformed visual assessments in detecting early tau burdens. Meta‐temporal and temporoparietal regions of interest excelled in early and late tau staging. Quantification methods correlated with plasma phosphorylated tau217 and cognitive decline. Findings were validated across two independent cohorts (Korea‐Registries to Overcome Dementia and Accelerate Dementia Research and Alzheimer's Disease Neuroimaging Initiative). The study highlights the complementary roles of visual and quantification methods.
- Top Cited PapersOpen Access
- 1 April 2025
- Published by American Medical Association (AMA) in JAMA Neurology
- Vol. 82 (4) , 344
Detection of Alzheimer Neuropathology in Alzheimer and Non-Alzheimer Clinical Syndromes With Blood-Based Biomarkers
Importance: Blood-based biomarkers for Alzheimer disease (AD) are clinically available, but their value is not well understood in syndromes typically associated with frontotemporal lobar degeneration syndromes (FTLD).Objective: To investigate the clinical importance and detectability of AD in FTLD-related neurodegenerative syndromes using 3 plasma biomarkers, phosphorylated tau 217 (p-tau217), neurofilament light chain (NfL), and glial fibrillary acidic protein (GFAP).Design, Setting, and Participants: This clinicopathological study took place at the University of California San Francisco Alzheimer Disease Research Center from August 2008 to July 2022. Autopsied individuals with clinical evaluation and neuropathological examination, diagnosed with clinical syndromes related to AD (n = 125), frontotemporal lobar degeneration (FTLD; n = 198), or cognitively unimpaired (CU) at the time of evaluation (n = 16) were included.Exposures: AD-related or FTLD-related clinical syndromes or CU.Main Outcomes and Measures: P-tau217, NfL, and GFAP were measured with single-molecule array (SIMOA). AD was defined as intermediate or high AD neuropathological change (ADNC) at autopsy. Clinical biomarker associations were evaluated using linear regressions. Imaging analyses used bayesian linear mixed-effects modeling.Results: A total of 349 individuals (191 [55%] male; mean [SD] age at death, 72 [11] years) were included. AD was common in both AD-related syndromes (110/125 [88%]) and FTLD-related syndromes (45/198 [23%]). Neuropathological stage at autopsy was higher in AD-related syndromes (high ADNC: 82/88 [93%] AD vs 13/23 [56%] FTLD), and AD was frequently considered a copathology in FTLD-related syndromes (30/198 [15%]). Plasma p-tau217 concentrations were higher in AD-related syndromes (mean [SD], 0.28 [0.16] pg/mL) than FTLD-related syndromes (mean [SD], 0.10 [0.09] pg/mL) (P < .05). Plasma p-tau217 concentrations were highest in atypical AD-related syndromes (mean [SD], 0.33 [0.02] pg/mL), followed by typical late-onset amnestic syndromes (mean [SD], 0.27 [0.03] pg/mL). FTLD-related syndromes with AD (mean [SD], 0.19 [0.02] pg/mL) were higher compared to without (mean [SD], 0.07 [0.00] pg/mL). Plasma p-tau217 detected AD neuropathology across syndromes (area under the receiver operating characteristic curve [AUC], 0.95; 95% CI, 0.93-0.97), with slightly better performance in AD-related syndromes (AUC, 0.98; 95% CI, 0.95-1.00) compared to FTLD-related syndromes (AUC, 0.89; 95% CI, 0.83-0.94). NfL and GFAP had lower performance for detecting AD (AUC, 0.73; 95% CI, 0.68-0.78 and AUC, 0.75; 95% CI, 0.67-0.80, respectively) and added little to no diagnostic value either alone or in combinations with p-tau217. The presence of AD in FTLD-related syndromes was associated with lower Mini-Mental State Examination score (mean [SD], −2.90 [1.09]; P < .05), worse performance on memory (mean [SD] z score, −0.64 [0.32]), executive (mean [SD] z score, −0.74 [0.19]), and visuospatial composites (mean [SD] z score, −0.88 [0.37]) as well as increased rates of posterior cortical atrophy.Conclusion: Clinically relevant AD was prevalent across neurodegenerative syndromes and detectable with plasma p-tau217. Plasma p-tau217 may be a useful tool to investigate the clinical impact of AD copathology in non-AD neurodegenerative syndromes, including the effect of disease-modifying therapies.
- 1 April 2025
- Published by American Medical Association (AMA) in JAMA Neurology
- Vol. 82 (4) , 344
Top Cited PapersOpen AccessDetection of Alzheimer Neuropathology in Alzheimer and Non-Alzheimer Clinical Syndromes With Blood-Based Biomarkers
Importance: Blood-based biomarkers for Alzheimer disease (AD) are clinically available, but their value is not well understood in syndromes typically associated with frontotemporal lobar degeneration syndromes (FTLD).Objective: To investigate the clinical importance and detectability of AD in FTLD-related neurodegenerative syndromes using 3 plasma biomarkers, phosphorylated tau 217 (p-tau217), neurofilament light chain (NfL), and glial fibrillary acidic protein (GFAP).Design, Setting, and Participants: This clinicopathological study took place at the University of California San Francisco Alzheimer Disease Research Center from August 2008 to July 2022. Autopsied individuals with clinical evaluation and neuropathological examination, diagnosed with clinical syndromes related to AD (n = 125), frontotemporal lobar degeneration (FTLD; n = 198), or cognitively unimpaired (CU) at the time of evaluation (n = 16) were included.Exposures: AD-related or FTLD-related clinical syndromes or CU.Main Outcomes and Measures: P-tau217, NfL, and GFAP were measured with single-molecule array (SIMOA). AD was defined as intermediate or high AD neuropathological change (ADNC) at autopsy. Clinical biomarker associations were evaluated using linear regressions. Imaging analyses used bayesian linear mixed-effects modeling.Results: A total of 349 individuals (191 [55%] male; mean [SD] age at death, 72 [11] years) were included. AD was common in both AD-related syndromes (110/125 [88%]) and FTLD-related syndromes (45/198 [23%]). Neuropathological stage at autopsy was higher in AD-related syndromes (high ADNC: 82/88 [93%] AD vs 13/23 [56%] FTLD), and AD was frequently considered a copathology in FTLD-related syndromes (30/198 [15%]). Plasma p-tau217 concentrations were higher in AD-related syndromes (mean [SD], 0.28 [0.16] pg/mL) than FTLD-related syndromes (mean [SD], 0.10 [0.09] pg/mL) (P < .05). Plasma p-tau217 concentrations were highest in atypical AD-related syndromes (mean [SD], 0.33 [0.02] pg/mL), followed by typical late-onset amnestic syndromes (mean [SD], 0.27 [0.03] pg/mL). FTLD-related syndromes with AD (mean [SD], 0.19 [0.02] pg/mL) were higher compared to without (mean [SD], 0.07 [0.00] pg/mL). Plasma p-tau217 detected AD neuropathology across syndromes (area under the receiver operating characteristic curve [AUC], 0.95; 95% CI, 0.93-0.97), with slightly better performance in AD-related syndromes (AUC, 0.98; 95% CI, 0.95-1.00) compared to FTLD-related syndromes (AUC, 0.89; 95% CI, 0.83-0.94). NfL and GFAP had lower performance for detecting AD (AUC, 0.73; 95% CI, 0.68-0.78 and AUC, 0.75; 95% CI, 0.67-0.80, respectively) and added little to no diagnostic value either alone or in combinations with p-tau217. The presence of AD in FTLD-related syndromes was associated with lower Mini-Mental State Examination score (mean [SD], −2.90 [1.09]; P < .05), worse performance on memory (mean [SD] z score, −0.64 [0.32]), executive (mean [SD] z score, −0.74 [0.19]), and visuospatial composites (mean [SD] z score, −0.88 [0.37]) as well as increased rates of posterior cortical atrophy.Conclusion: Clinically relevant AD was prevalent across neurodegenerative syndromes and detectable with plasma p-tau217. Plasma p-tau217 may be a useful tool to investigate the clinical impact of AD copathology in non-AD neurodegenerative syndromes, including the effect of disease-modifying therapies.
- Open Access
- 1 January 2025
- Published by XMLink in Dementia and Neurocognitive Disorders
- Vol. 24 (4) , 209-232
Executive Summary of 2025 International Conference of the Korean Dementia Association and International Congress of the Asian Society Against Dementia (IC-KDA/ASAD 2025): A Report From the Academic Committee of the Korean Dementia Association
Kim J, et al. Dement Neurocogn Disord. 2025 Oct;24(4):209-232. https://doi.org/10.12779/dnd.2025.24.4.209
- 1 January 2025
- Published by XMLink in Dementia and Neurocognitive Disorders
- Vol. 24 (4) , 209-232
Open AccessExecutive Summary of 2025 International Conference of the Korean Dementia Association and International Congress of the Asian Society Against Dementia (IC-KDA/ASAD 2025): A Report From the Academic Committee of the Korean Dementia Association
Kim J, et al. Dement Neurocogn Disord. 2025 Oct;24(4):209-232. https://doi.org/10.12779/dnd.2025.24.4.209
- Open Access
- 1 December 2024
- Published by Wiley in Alzheimer's & Dementia
- Vol. 20 (S2) , e090596
Diagnostic Performance of Plasma P‐tau217, NfL, and GFAP for Predicting Alzheimer’s Disease Neuropathology Across Diverse Neurodegenerative Syndromes
Background: In the era of disease‐modifying treatments for Alzheimer's disease (AD), accurate detection of underlying AD pathology is critical. Blood‐based biomarkers for AD are increasingly available, but their diagnostic performance is not well‐understood across the spectrum of neurodegenerative disease, especially when AD presents as co‐pathology in non‐AD syndromes. We investigated the diagnostic performance of three plasma biomarkers (phosphorylated tau 217 [p‐tau217], neurofilament light chain [NfL], and glial fibrillary acidic protein [GFAP]) to detect AD, confirmed by autopsy, across 12 clinical neurodegenerative syndromes with various underlying etiologies.Methods: A total of 349 individuals with ante‐mortem blood samples and post‐mortem neuropathological examination were included at UCSF between August 2008 and March 2021. The participants were clinically diagnosed with syndromes related to AD, frontotemporal lobar degeneration (FTLD), or dementia with Lewy bodies (DLB) or were cognitively unimpaired (CU) controls. Quantification of p‐tau217, NfL, and GFAP was performed using SiMoA assay by Janssen. Clinically relevant AD neuropathology was defined as intermediate or high AD neuropathological changes (ADNC ≥ 2).Results: Significant AD neuropathology was observed in 88% (110/125) of AD‐related syndromes and 23% (45/198) of FTLD‐related syndromes. Plasma p‐tau217 levels were higher on average in AD‐related syndromes (0.28±0.16pg/mL) compared to FTLD‐related syndromes (0.10±0.09pg/mL, p<0.001). All AD‐related syndromes, except for mild cognitive impairment, showed significantly increased p‐tau217 levels compared to CU (0.10±0.08pg/mL, p<0.001). No significant differences were observed in NfL and GFAP levels when directly comparing AD‐related (31±28pg/mL[NfL], 267±131pg/mL[GFAP]) and FTLD‐related syndromes (50±50pg/mL[NfL], 201±155pg/mL[GFAP]) or either group with CU (32±14pg/mL[NfL], 235±67pg/mL[GFAP]). Plasma p‐tau217 demonstrated excellent diagnostic accuracy in detecting AD neuropathology, achieving an AUC of 0.975[0.946‐1.000] in AD‐related syndromes (0.973 sensitivity and 0.800 specificity) and 0.888[0.831‐0.944] in FTLD‐related syndromes (0.467 sensitivity and 0.961 specificity). In contrast, NfL and GFAP showed lower diagnostic performance in AD‐related syndromes (AUC=0.857[0.748‐0.966] and AUC=0.809[0.661‐0.956], respectively) and even less accuracy in FTLD‐related syndromes (AUC=0.740[0.662‐0.740] and AUC=0.755[0.679‐0.831], respectively).Conclusion: AD neuropathology was prevalent across diverse neurodegeneration syndromes, both as primary and co‐pathology. Our findings suggest that plasma p‐tau217 could be a useful tool for identification of AD neuropathology in the presence of non‐AD neurodegenerative syndromes, potentially for identifying populations for investigation of effects of AD treatments.
- 1 December 2024
- Published by Wiley in Alzheimer's & Dementia
- Vol. 20 (S2) , e090596
Open AccessDiagnostic Performance of Plasma P‐tau217, NfL, and GFAP for Predicting Alzheimer’s Disease Neuropathology Across Diverse Neurodegenerative Syndromes
Background: In the era of disease‐modifying treatments for Alzheimer's disease (AD), accurate detection of underlying AD pathology is critical. Blood‐based biomarkers for AD are increasingly available, but their diagnostic performance is not well‐understood across the spectrum of neurodegenerative disease, especially when AD presents as co‐pathology in non‐AD syndromes. We investigated the diagnostic performance of three plasma biomarkers (phosphorylated tau 217 [p‐tau217], neurofilament light chain [NfL], and glial fibrillary acidic protein [GFAP]) to detect AD, confirmed by autopsy, across 12 clinical neurodegenerative syndromes with various underlying etiologies.Methods: A total of 349 individuals with ante‐mortem blood samples and post‐mortem neuropathological examination were included at UCSF between August 2008 and March 2021. The participants were clinically diagnosed with syndromes related to AD, frontotemporal lobar degeneration (FTLD), or dementia with Lewy bodies (DLB) or were cognitively unimpaired (CU) controls. Quantification of p‐tau217, NfL, and GFAP was performed using SiMoA assay by Janssen. Clinically relevant AD neuropathology was defined as intermediate or high AD neuropathological changes (ADNC ≥ 2).Results: Significant AD neuropathology was observed in 88% (110/125) of AD‐related syndromes and 23% (45/198) of FTLD‐related syndromes. Plasma p‐tau217 levels were higher on average in AD‐related syndromes (0.28±0.16pg/mL) compared to FTLD‐related syndromes (0.10±0.09pg/mL, p<0.001). All AD‐related syndromes, except for mild cognitive impairment, showed significantly increased p‐tau217 levels compared to CU (0.10±0.08pg/mL, p<0.001). No significant differences were observed in NfL and GFAP levels when directly comparing AD‐related (31±28pg/mL[NfL], 267±131pg/mL[GFAP]) and FTLD‐related syndromes (50±50pg/mL[NfL], 201±155pg/mL[GFAP]) or either group with CU (32±14pg/mL[NfL], 235±67pg/mL[GFAP]). Plasma p‐tau217 demonstrated excellent diagnostic accuracy in detecting AD neuropathology, achieving an AUC of 0.975[0.946‐1.000] in AD‐related syndromes (0.973 sensitivity and 0.800 specificity) and 0.888[0.831‐0.944] in FTLD‐related syndromes (0.467 sensitivity and 0.961 specificity). In contrast, NfL and GFAP showed lower diagnostic performance in AD‐related syndromes (AUC=0.857[0.748‐0.966] and AUC=0.809[0.661‐0.956], respectively) and even less accuracy in FTLD‐related syndromes (AUC=0.740[0.662‐0.740] and AUC=0.755[0.679‐0.831], respectively).Conclusion: AD neuropathology was prevalent across diverse neurodegeneration syndromes, both as primary and co‐pathology. Our findings suggest that plasma p‐tau217 could be a useful tool for identification of AD neuropathology in the presence of non‐AD neurodegenerative syndromes, potentially for identifying populations for investigation of effects of AD treatments.
- Open Access
- 25 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S16)
Longitudinal changes of amyloid (A) and tau (T) image‐based biomarker in Alzheimer’s disease spectrum
Background: To investigate long‐term changes in dichotomous profiles of amyloid (A) and tau (T) image‐based biomarker in Alzheimer’s disease (AD) spectrum.Method: During the initial visit (V1), a total of 275 participants [96 cognitively unimpaired (CU), 108 mild cognitive impairment (MCI), and 71 AD] who completed 18F‐florbetaben and 18F‐flortaucipir PET studies were followed up to three times. Two years later, 189 participants (74 CU, 77 MCI, and 38 AD) were enrolled in the second visit (V2), and 83 participants (34 CU, 39 MCI, and 10 AD) were enrolled in the third visit (V3) five years later (mean 4.8 years) to complete the same PET studies. The A and T biomarker profile was determined based on the cut‐off standardized uptake value ratio of the most vulnerable region in each pathology.Result: In A‐ participants, 5.4% (6/111) of participants converted to A+ at V2 and 17.9% (7/39) converted to A+ at V3. Likewise, 2.9% (4/138) of participants in T‐ participants converted to T+ at V2, and 17.7% (11/62) converted from T‐ to T+ at V3. Compared to the low conversion rate from T‐ to T+ in A‐T‐ participants [0.9% (1 A‐T+ / 106 A‐T‐) at V2 and 5.1% (2 A+T+ / 39 A‐T‐)] at V3, A+T‐ participants showed higher conversion rates from T‐ to T+ [9.4% (3 A+T+ / 32 A+T‐) at V2 and 39.1% (9 A+T+ / 23 A+T‐) at V3].Conclusion: The conversion of the at biomarker profile was observed more prominently in the long term than in the short term, and the conversion of the T biomarker in A+ compared to A‐ was over seven times more frequent in five years follow‐up.
- 25 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S16)
Open AccessLongitudinal changes of amyloid (A) and tau (T) image‐based biomarker in Alzheimer’s disease spectrum
Background: To investigate long‐term changes in dichotomous profiles of amyloid (A) and tau (T) image‐based biomarker in Alzheimer’s disease (AD) spectrum.Method: During the initial visit (V1), a total of 275 participants [96 cognitively unimpaired (CU), 108 mild cognitive impairment (MCI), and 71 AD] who completed 18F‐florbetaben and 18F‐flortaucipir PET studies were followed up to three times. Two years later, 189 participants (74 CU, 77 MCI, and 38 AD) were enrolled in the second visit (V2), and 83 participants (34 CU, 39 MCI, and 10 AD) were enrolled in the third visit (V3) five years later (mean 4.8 years) to complete the same PET studies. The A and T biomarker profile was determined based on the cut‐off standardized uptake value ratio of the most vulnerable region in each pathology.Result: In A‐ participants, 5.4% (6/111) of participants converted to A+ at V2 and 17.9% (7/39) converted to A+ at V3. Likewise, 2.9% (4/138) of participants in T‐ participants converted to T+ at V2, and 17.7% (11/62) converted from T‐ to T+ at V3. Compared to the low conversion rate from T‐ to T+ in A‐T‐ participants [0.9% (1 A‐T+ / 106 A‐T‐) at V2 and 5.1% (2 A+T+ / 39 A‐T‐)] at V3, A+T‐ participants showed higher conversion rates from T‐ to T+ [9.4% (3 A+T+ / 32 A+T‐) at V2 and 39.1% (9 A+T+ / 23 A+T‐) at V3].Conclusion: The conversion of the at biomarker profile was observed more prominently in the long term than in the short term, and the conversion of the T biomarker in A+ compared to A‐ was over seven times more frequent in five years follow‐up.
- Open Access
- 25 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S16)
Amyloid/Tau/Neurodegeneration (ATN) image‐based biomarker trajectories of Alzheimer’s disease through 5‐year longitudinal follow‐up
Background: To investigate the progression of Alzheimer’s disease (AD) in image‐based Amyloid/Tau/Neurodegeneration (ATN) biomarkers through 5‐year longitudinal follow‐up.Method: Among the participants who completed 18F‐florbetaben (FBB) for amyloid and 18F‐flortaucipir (FTP) for tau positron emission tomography (PET), and brain magnetic resonance (MR) imaging for neurodegeneration at a first visit, we enrolled the 145 participants who the studies at least twice [67 amyloid negative cognitive unimpaired (A‐CU), 10 amyloid positive cognitive unimpaired (A+CU), 68 amyloid positive cognitive impaired (A+CI)]. 70 participants completed the scans twice (25.2±3.1, months), and 75 participants completed the scans three times (57.9±7.4, months). We estimated the temporal trajectories of ATN biomarkers using a restricted cubic spline model and modified Euler method between baseline and annual change rates. The standardized uptake value ratio of FBB/FTP PET and hippocampal volume were used for representing each ATN biomarker, respectively.Result: The FBB curve of the global cortex and AD‐specific regions reaches a plateau with a sigmoid appearance. FTP curves in the regions for Braak stages I‐II and III‐IV show similar sigmoid appearance while the global cortical and stage V‐VI tau curves show an exponential increase continuously. The hippocampal volume curve shows a linear decrease until the time point when the tau accumulation begins in the Braak stage I‐II, then decreases to a reversed sigmoid appearance.Conclusion: Like the already known saturation of amyloid burden, it was also shown that the tau burden of the region for Braak stages I‐II and III‐IV saturated, but not in Braak stages V‐VI. Hippocampal atrophy seems to accelerate when tau begins to accumulate in early Braak stage regions. In future work, it is necessary to enroll patients at an advanced stage and collaborate with an international cohort.
- 25 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S16)
Open AccessAmyloid/Tau/Neurodegeneration (ATN) image‐based biomarker trajectories of Alzheimer’s disease through 5‐year longitudinal follow‐up
Background: To investigate the progression of Alzheimer’s disease (AD) in image‐based Amyloid/Tau/Neurodegeneration (ATN) biomarkers through 5‐year longitudinal follow‐up.Method: Among the participants who completed 18F‐florbetaben (FBB) for amyloid and 18F‐flortaucipir (FTP) for tau positron emission tomography (PET), and brain magnetic resonance (MR) imaging for neurodegeneration at a first visit, we enrolled the 145 participants who the studies at least twice [67 amyloid negative cognitive unimpaired (A‐CU), 10 amyloid positive cognitive unimpaired (A+CU), 68 amyloid positive cognitive impaired (A+CI)]. 70 participants completed the scans twice (25.2±3.1, months), and 75 participants completed the scans three times (57.9±7.4, months). We estimated the temporal trajectories of ATN biomarkers using a restricted cubic spline model and modified Euler method between baseline and annual change rates. The standardized uptake value ratio of FBB/FTP PET and hippocampal volume were used for representing each ATN biomarker, respectively.Result: The FBB curve of the global cortex and AD‐specific regions reaches a plateau with a sigmoid appearance. FTP curves in the regions for Braak stages I‐II and III‐IV show similar sigmoid appearance while the global cortical and stage V‐VI tau curves show an exponential increase continuously. The hippocampal volume curve shows a linear decrease until the time point when the tau accumulation begins in the Braak stage I‐II, then decreases to a reversed sigmoid appearance.Conclusion: Like the already known saturation of amyloid burden, it was also shown that the tau burden of the region for Braak stages I‐II and III‐IV saturated, but not in Braak stages V‐VI. Hippocampal atrophy seems to accelerate when tau begins to accumulate in early Braak stage regions. In future work, it is necessary to enroll patients at an advanced stage and collaborate with an international cohort.
- Open Access
- 9 December 2023
- Published by Springer Nature in Nature Communications
- Vol. 14 (1) , 1-15
Amplified fluorogenic immunoassay for early diagnosis and monitoring of Alzheimer’s disease from tear fluid
Accurate diagnosis of Alzheimer’s disease (AD) in its earliest stage can prevent the disease and delay the symptoms. Therefore, more sensitive, non-invasive, and simple screening tools are required for the early diagnosis and monitoring of AD. Here, we design a self-assembled nanoparticle-mediated amplified fluorogenic immunoassay (SNAFIA) consisting of magnetic and fluorophore-loaded polymeric nanoparticles. Using a discovery cohort of 21 subjects, proteomic analysis identifies adenylyl cyclase-associated protein 1 (CAP1) as a potential tear biomarker. The SNAFIA demonstrates a low detection limit (236 aM), good reliability (R2 = 0.991), and a wide analytical range (0.320–1000 fM) for CAP1 in tear fluid. Crucially, in the verification phase with 39 subjects, SNAFIA discriminates AD patients from healthy controls with 90% sensitivity and 100% specificity in under an hour. Utilizing tear fluid as a liquid biopsy, SNAFIA could potentially aid in long-term care planning, improve clinical trial efficiency, and accelerate therapeutic development for AD.
- 9 December 2023
- Published by Springer Nature in Nature Communications
- Vol. 14 (1) , 1-15
Open AccessAmplified fluorogenic immunoassay for early diagnosis and monitoring of Alzheimer’s disease from tear fluid
Accurate diagnosis of Alzheimer’s disease (AD) in its earliest stage can prevent the disease and delay the symptoms. Therefore, more sensitive, non-invasive, and simple screening tools are required for the early diagnosis and monitoring of AD. Here, we design a self-assembled nanoparticle-mediated amplified fluorogenic immunoassay (SNAFIA) consisting of magnetic and fluorophore-loaded polymeric nanoparticles. Using a discovery cohort of 21 subjects, proteomic analysis identifies adenylyl cyclase-associated protein 1 (CAP1) as a potential tear biomarker. The SNAFIA demonstrates a low detection limit (236 aM), good reliability (R2 = 0.991), and a wide analytical range (0.320–1000 fM) for CAP1 in tear fluid. Crucially, in the verification phase with 39 subjects, SNAFIA discriminates AD patients from healthy controls with 90% sensitivity and 100% specificity in under an hour. Utilizing tear fluid as a liquid biopsy, SNAFIA could potentially aid in long-term care planning, improve clinical trial efficiency, and accelerate therapeutic development for AD.